Thrombolysis 3 to 4.5 hours after acute ischemic stroke [1]

New England Journal of Medicine

Volumn 359, Issue 26, 2008, Pages 2840-

  Fitzpatrick, Aine E ^a   Noone, Imelda ^a   O'Shea, Diarmuid D ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

HUMAN; LETTER; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; PRIORITY JOURNAL; STROKE; TELEMEDICINE; UNITED STATES; AGE; AGED; BRAIN ISCHEMIA; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; NOTE; TIME;

AGE FACTORS; AGED, 80 AND OVER; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 58149099851     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Noone I, O'Shea D, Crowe M. Stroke in the very old. Ir Med J 2008;101:8-9.
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
3. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
4. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial. JAMA 1999;282:2019-26.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.